Cargando…

TAMing pancreatic cancer: combat with a double edged sword

Among all the deadly cancers, pancreatic cancer ranks seventh in mortality. The absence of any grave symptoms coupled with the unavailability of early prognostic and diagnostic markers make the disease incurable in most of the cases. This leads to a late diagnosis, where the disease would have aggra...

Descripción completa

Detalles Bibliográficos
Autores principales: Lankadasari, Manendra Babu, Mukhopadhyay, Pramiti, Mohammed, Sabira, Harikumar, Kuzhuvelil B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441154/
https://www.ncbi.nlm.nih.gov/pubmed/30925924
http://dx.doi.org/10.1186/s12943-019-0966-6
_version_ 1783407503873146880
author Lankadasari, Manendra Babu
Mukhopadhyay, Pramiti
Mohammed, Sabira
Harikumar, Kuzhuvelil B.
author_facet Lankadasari, Manendra Babu
Mukhopadhyay, Pramiti
Mohammed, Sabira
Harikumar, Kuzhuvelil B.
author_sort Lankadasari, Manendra Babu
collection PubMed
description Among all the deadly cancers, pancreatic cancer ranks seventh in mortality. The absence of any grave symptoms coupled with the unavailability of early prognostic and diagnostic markers make the disease incurable in most of the cases. This leads to a late diagnosis, where the disease would have aggravated and thus, incurable. Only around 20% of the cases present the early disease diagnosis. Surgical resection is the prime option available for curative local disease but in the case of advanced cancer, chemotherapy is the standard treatment modality although the patients end up with drug resistance and severe side effects. Desmoplasia plays a very important role in chemoresistance associated with pancreatic cancer and consists of a thick scar tissue around the tumor comprised of different cell populations. The interplay between this heterogenous population in the tumor microenvironment results in sustained tumor growth and metastasis. Accumulating evidences expose the crucial role played by the tumor-associated macrophages in pancreatic cancer and this review briefly presents the origin from their parent lineage and the importance in maintaining tumor hallmarks. Finally we have tried to address their role in imparting chemoresistance and the therapeutic interventions leading to reduced tumor burden.
format Online
Article
Text
id pubmed-6441154
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64411542019-04-11 TAMing pancreatic cancer: combat with a double edged sword Lankadasari, Manendra Babu Mukhopadhyay, Pramiti Mohammed, Sabira Harikumar, Kuzhuvelil B. Mol Cancer Review Among all the deadly cancers, pancreatic cancer ranks seventh in mortality. The absence of any grave symptoms coupled with the unavailability of early prognostic and diagnostic markers make the disease incurable in most of the cases. This leads to a late diagnosis, where the disease would have aggravated and thus, incurable. Only around 20% of the cases present the early disease diagnosis. Surgical resection is the prime option available for curative local disease but in the case of advanced cancer, chemotherapy is the standard treatment modality although the patients end up with drug resistance and severe side effects. Desmoplasia plays a very important role in chemoresistance associated with pancreatic cancer and consists of a thick scar tissue around the tumor comprised of different cell populations. The interplay between this heterogenous population in the tumor microenvironment results in sustained tumor growth and metastasis. Accumulating evidences expose the crucial role played by the tumor-associated macrophages in pancreatic cancer and this review briefly presents the origin from their parent lineage and the importance in maintaining tumor hallmarks. Finally we have tried to address their role in imparting chemoresistance and the therapeutic interventions leading to reduced tumor burden. BioMed Central 2019-03-30 /pmc/articles/PMC6441154/ /pubmed/30925924 http://dx.doi.org/10.1186/s12943-019-0966-6 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Lankadasari, Manendra Babu
Mukhopadhyay, Pramiti
Mohammed, Sabira
Harikumar, Kuzhuvelil B.
TAMing pancreatic cancer: combat with a double edged sword
title TAMing pancreatic cancer: combat with a double edged sword
title_full TAMing pancreatic cancer: combat with a double edged sword
title_fullStr TAMing pancreatic cancer: combat with a double edged sword
title_full_unstemmed TAMing pancreatic cancer: combat with a double edged sword
title_short TAMing pancreatic cancer: combat with a double edged sword
title_sort taming pancreatic cancer: combat with a double edged sword
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441154/
https://www.ncbi.nlm.nih.gov/pubmed/30925924
http://dx.doi.org/10.1186/s12943-019-0966-6
work_keys_str_mv AT lankadasarimanendrababu tamingpancreaticcancercombatwithadoubleedgedsword
AT mukhopadhyaypramiti tamingpancreaticcancercombatwithadoubleedgedsword
AT mohammedsabira tamingpancreaticcancercombatwithadoubleedgedsword
AT harikumarkuzhuvelilb tamingpancreaticcancercombatwithadoubleedgedsword